Bextra Meta-Analysis Affirms Safety Profile, Pfizer Tells Physicians

A meta-analysis of Bextra (valdecoxib) clinical trials in osteoarthritis and rheumatoid arthritis show the agent has a lower incidence of myocardial infarctions compared to traditional NSAIDs, Pfizer maintains in Dec. 2 "medical information letters.